Tricky Business: Rethinking Our Approach to Tackling Schizophrenia

Current standards of care for schizophrenia, generally targeting the dopaminergic pathway, demonstrate efficacy in positive symptoms in patients, but with varied results for other symptoms. Unresolved negative symptoms, and symptoms related to cognitive impairment associated with schizophrenia (CIAS), represent unmet patient needs that may be addressed with newer therapies targeting newly proposed, non-dopaminergic pathways. Clinicians in psychiatry may benefit from understanding how deficits in current treatment options for schizophrenia and CIAS may be addressed given research related to the pathophysiology of schizophrenia and medical needs of patients.

In this live CME Outfitters webcast entitled, Tricky Business: Rethinking Our Approach to Tackling Schizophrenia, a panel of expert faculty will utilize animated 3-D models to discuss pathophysiology, negative symptomology, and CIAS in schizophrenia, identify the impact of unmet patient medical needs and examine current emerging therapies in the treatment of schizophrenia.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

Translate non-dopaminergic pathophysiology to the manifestation of cognitive impairment and negative symptoms in schizophrenia.
Identify the impact of disease including unmet medical needs and deficiencies associated with CIAS on patients with schizophrenia.
Examine current and emerging therapies for CIAS, factoring in limitations as part of management strategies.

Financial Support

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Psychiatrists, nurse practitioners (NPs), and physician associates (PAs) specializing in psychiatry.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Correll reports the following financial relationships:

Advisory Board: AbbVie Inc.; Allergan; Angelini Pharma Inc; Biogen; Compass Therapeutics, Inc.; Gedeon Richter; Janssen Pharmaceuticals, Inc./J&J; Karuna Therapeutics; Lundbeck; MedInCell; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc; Recordati; Rovi; Sage Therapeutics, Inc; Seqirus; SK Life Science, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc; Axsome Therapeutics, Inc.; Cardio Diagnostics Inc.; Cerevel Therapeutics; COMPASS Pathways; Gedeon Richter; Holmusk; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals, Inc./J&J; Karuna Therapeutics; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Medscape; Merck & Co., Inc.; Mindpax; Mylan; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Rovi; Seqirus; Servier; SK Life Science, Inc.; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Grants and Research Support: Janssen Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.

Stock Shareholder (ownership interest): Cardio Diagnostics Inc.; Mindpax; LB Pharma; PsiloSterics; and Quantic (Options)

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
Mary Gleason, PhD (planning committee)
John Jones, PharmD (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sandra Caballero, PharmD (planning committee)
Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Live Webcast: